Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05515406 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
A Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Ono Pharmaceutical Co..
- Active
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 10
- Study locations
NCT05515406: Active Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Ono Pharmaceutical Co..
NCT05515406 is a Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell that is active but no longer recruiting, run by Ono Pharmaceutical Co.. The registered enrollment target is 108 participants, below the 387-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (72% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05515406, a Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell, is active but no longer recruiting, sponsored by Ono Pharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).
Primary Outcome
MTD will be estimated based on Dose limiting toxicity (DLT) observed during the first 3 weeks of treatment
Conditions Studied
Interventions
- DRUG ONO-7018
Study Locations (10)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
Texas
- Baylor Scott & White Research Institute - Dallas
- MD Anderson Cancer Center - Houston
California
- Jonsson Comprehensive Cancer Center - Santa Monica
Missouri
- AMR Kansas City - Kansas City
North Carolina
- Leo Jenkins Cancer Center/ECU School of Medicine - Greenville
Ohio
- University of Cincinnati - Cincinnati
Tennessee
- Sarah Cannon Research Institute - Nashville
Washington
- Northwest Medical Specialities - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What the registry record for NCT05515406 still lists
NCT05515406 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 387-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which ONO-7018 is the first listed.
NCT05515406 lists 10 locations in 8 states (Pennsylvania, Texas, California).
Frequently Asked Questions
What is clinical trial NCT05515406 about?
NCT05515406 is a clinical study titled "A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL". This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2).
What is the current status of trial NCT05515406?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2023-02-13. Estimated completion is 2027-12.
What conditions does trial NCT05515406 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell.
What interventions are being tested in trial NCT05515406?
The interventions under investigation include: ONO-7018 (DRUG).
Who is sponsoring clinical trial NCT05515406?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05515406 being conducted?
This trial has 10 study locations across California, Missouri, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05515406's enrollment target sits among peer trials
108 26th of 58 higher than 33 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI